Presented in abstract format at the American Society of Clinical Oncology Genitourinary Symposium; March 5-7, 2010; San Francisco, CA; and the American Society of Clinical Oncology Annual Meeting; June 4-7, 2010; Chicago, IL.
Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma
Article first published online: 8 OCT 2013
© 2013 American Cancer Society
Volume 120, Issue 1, pages 52–60, 1 January 2014
How to Cite
Halabi, S., Rini, B., Escudier, B., Stadler, W. M. and Small, E. J. (2014), Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma. Cancer, 120: 52–60. doi: 10.1002/cncr.28221
We thank Roche for sharing the AVOREN dataset. In addition, the authors thank Drs. Peter Compton, George Kong, and Nicola Moore for answering questions regarding the AVOREN database.
See editorial on pages 7–10, this issue.
- Issue published online: 17 DEC 2013
- Article first published online: 8 OCT 2013
- Manuscript Accepted: 21 MAY 2013
- Manuscript Revised: 16 MAY 2013
- Manuscript Received: 26 MAR 2013
- renal cancer;
- clinical trials;
- progression-free survival;
- overall survival
The current study was conducted to investigate the dependence between progression-free survival (PFS) and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC) and to explore whether PFS can be used as an intermediate endpoint of OS in this patient population.
A total of 1381 patients from 2 prospective phase 3 trials (Cancer and Leukemia Group B [CALGB] 90206 and AVOREN) of interferon-alpha with or without bevacizumab were analyzed. Both trials recruited previously untreated patients with clear cell mRCC with an Eastern Cooperative Oncology Group performance status of 0 to 2; adequate bone marrow, hepatic, cardiac, and renal function; and controlled blood pressure. The CALGB study served as the training data set, and the AVOREN study served as the testing data set. The dependence between PFS and OS was investigated using the Kendall tau for bivariate time-to-event endpoints.
In the training data set, the median OS times among patients who experienced progressive disease at 3 months or 6 months were 6 months and 8 months, respectively, compared with 25 months and 30 months, respectively, (P < .001) in patients who did not develop disease progress. The adjusted hazard ratios (HR) were 2.6 (P < .0001) and 2.8 (P < .0001), respectively, for patients who did and did not progress at 3 months or 6 months. The dependence between PFS and OS was 0.53. These associations were confirmed in the testing data set.
In patients with mRCC who were treated with interferon-alpha with or without bevacizumab, the PFS at 3 months and 6 months was found to be predictive of OS. A high dependence between PFS and OS was observed, suggesting that PFS may be used as a surrogate endpoint for OS. Although this is a novel observation for RCC, these findings require validation in patients with mRCC who are treated with other targeted agents. Cancer 2014;120:52–60. © 2013 American Cancer Society.